Published in BMC Cancer on July 25, 2007
SOCS proteins in development and disease. Am J Clin Exp Immunol (2013) 1.17
Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer (2010) 1.15
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res (2011) 1.01
The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res (2009) 0.99
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer (2014) 0.89
Physical confirmation and mapping of overlapping rat mammary carcinoma susceptibility QTLs, Mcs2 and Mcs6. PLoS One (2011) 0.88
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma (2014) 0.87
Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res (2009) 0.87
Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis. Cell Death Differ (2011) 0.85
Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J Cell Biochem (2012) 0.85
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer. Br J Cancer (2014) 0.84
Suppressor of cytokine signaling-2 gene disruption promotes Apc(Min/+) tumorigenesis and activator protein-1 activation. Am J Pathol (2010) 0.82
Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol (2014) 0.82
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
Differential Expression of Ccn4 and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells. Cancer Genomics Proteomics (2016) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev (1997) 5.57
SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem (2002) 4.84
Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol (2004) 4.45
Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell (2003) 4.37
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol (2004) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun (1997) 2.51
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Gigantism in mice lacking suppressor of cytokine signalling-2. Nature (2000) 2.25
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem (1999) 1.74
Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol (2004) 1.70
SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest (2005) 1.66
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem (2000) 1.58
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene (2005) 1.55
Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene (2004) 1.51
STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology (2001) 1.47
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol (2002) 1.39
Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene (2002) 1.38
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J (1999) 1.33
The tumor suppressor activity of SOCS-1. Oncogene (2002) 1.29
Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem (2002) 1.26
Negative regulation of FAK signaling by SOCS proteins. EMBO J (2003) 1.26
Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer (2006) 1.24
Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A (2003) 1.18
Prognosis in stage II (T1N1M0) breast cancer. Ann Surg (1981) 1.16
The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia (2000) 1.08
Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer (2003) 1.05
Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett (1999) 1.05
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer (2004) 1.03
Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology (2004) 0.94
Haplotype insufficiency for suppressor of cytokine signaling-2 enhances intestinal growth and promotes polyp formation in growth hormone-transgenic mice. Endocrinology (2006) 0.93
Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat (2006) 0.92
Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene (2000) 0.91
STAT 5a expression in various lesions of the breast. Virchows Arch (2005) 0.90
Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol (2005) 0.88
Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat (2004) 0.87
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res (2003) 2.14
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
Circulating tumor cells in metastatic breast cancer--toward individualized treatment? N Engl J Med (2004) 1.89
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat (2012) 1.77
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol (2004) 1.45
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol (2003) 1.31
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood (2006) 1.18
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol (2006) 1.18
Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet (2011) 1.16
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch (2002) 1.12
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Conservative management of abnormally invasive placenta: four case reports. Acta Obstet Gynecol Scand (2013) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res (2014) 1.04
Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol (2004) 1.03
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr (2010) 1.02
Mammaglobin expression in gynecologic malignancies and malignant effusions detected by nested reverse transcriptase-polymerase chain reaction. Lab Invest (2002) 1.02
High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J (2004) 1.01
Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. Gynecol Oncol (2011) 0.99
Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene (2004) 0.99
Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.99
Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res (2003) 0.99
Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem (2004) 0.98
Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol (2006) 0.97
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res (2004) 0.96
CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer (2004) 0.95
Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology (2012) 0.94
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Invest (2009) 0.94
Multiple sequence variants of BRCA2 exon 7 alter splicing regulation. J Med Genet (2012) 0.94
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol (2012) 0.93
Selective response to insulin versus insulin-like growth factor-I and -II and up-regulation of insulin receptor splice variant B in the differentiated mouse mammary epithelium. Endocrinology (2009) 0.93
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res (2006) 0.92
Interaction and functional interference of glucocorticoid receptor and SOCS1. J Biol Chem (2008) 0.92
DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem (2004) 0.91
Effect of tension-free vaginal tape operation on urethral closure function. Urology (2006) 0.91
Elevated prolactin redirects secretory vesicle traffic in rabbit lacrimal acinar cells. Am J Physiol Endocrinol Metab (2006) 0.91
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res (2010) 0.90
HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol (2012) 0.90
DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. Gynecol Oncol (2011) 0.90
Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. J Cancer Res Clin Oncol (2012) 0.90
In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol (2014) 0.90
Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol (2006) 0.90